This phase 2 randomized trial reports that spores of nontoxigenic Clostridium difficile strain M3 were well tolerated, appeared to be safe, and reduced recurrence of C difficile infection (CDI) among patients who had previously had CDI treated with metronidazole or vancomycin.
This cohort study reports the effects of an oral fixed-dose regimen of daclatasvir, asunaprevir, and beclabuvir on sustained virologic response in patients without cirrhosis who had chronic hepatitis C virus infection.
This open-label uncontrolled study of patients with chronic HCV genotype 1 infection and cirrhosis reports high rates of SVR12 in those who received a 12-week oral fixed-dose regimen of daclatasvir, asunaprevir, and beclabuvir, with or without ribavirin.
This Viewpoint discusses the need for leaders in health care to steer the next phase of health care reform.
This Viewpoint discusses issues for improvement of the Affordable Care Act.
This Viewpoint discusses the importance of the family health history and the need for novel family history tools in the changing health care environment.
This Viewpoint lists some recommendations to improve epidural steroid injections that were developed by a multidisciplinary working group.
This Viewpoint describes clinical progress in eradicating hepatitis C virus infection, but emphasizes the importance of making treatment more cost-effective and accessible to all patients.
Create a personal account or sign in to: